TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01188772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir tablets were administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir tablets were administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match sofosbuvir
Description: Placebo tablets to match sofosbuvir were administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match sofosbuvir
Description: Placebo tablets to match sofosbuvir were administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
Study: NCT03040141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of VIS410
Description: Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of VIS410
Description: Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of placebo in addition to oseltamivir
Study: NCT04296760

Intervention type: DIAGNOSTIC_TEST
Intervention: Rectal water-contrast transvaginal ultrasonography
Description: Transvaginal ultrasound scan combined with the introduction of saline solution into the rectum

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonovaginography
Description: Transvaginal ultrasound scan combined with the introduction of saline solution into the vagina
Study: NCT00647764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 Mesylate Hsp90 inhibitor
Description: dose escalated, tablets twice a week; undetermined duration until disease progression
Study: NCT04602403

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rigid ureteroscopy
Description: endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rigid ureteroscopy
Description: endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
Study: NCT00626444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C
Description: Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
Study: NCT02196961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: adjuvant treatment of completely resected Merkel cell carcinoma
Study: NCT01863823

Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin and Tetracyclines
Description: 202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.

Intervention type: DRUG
Group type: OTHER
Intervention: Mouth washing
Description: Two time washing mouth per day
Study: NCT00002998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT02364908

Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education
Description: This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
Study: NCT04268186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AFz and CPz of the 10-10 electrode system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. The configuration used will be optimized to stimulate key nodes connected to MCC, including anterior insula, MFG and supramarginal gyrus, and designed using an individual head model that will be combined with each subject's measured connectivity map. The number of electrodes will be minimally 2 and maximally 32.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Transcranial direct current stimulation (tDCS) will be applied. Stimulation amplitude is 2 mA. Stimulation duration is 20 minutes. Placebo stimulation will be applied by ramping the current up and immediately down over 30 seconds. The configuration used is two electrodes at AF3 and AF4 of the 10-10 electrode system.
Study: NCT01596803

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Taking of blood
Description: Taking venous blood samples to analyse oxidant stress

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Taking of blood
Description: Taking venous blood samples to analyse oxidant stress

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: needle biopsy of the vastus lateralis muscle
Description: T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: needle biopsy of the vastus lateralis muscle
Description: T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit C Vit E Zn Se
Description: T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vit E Placebo Vit C Zn Se
Description: venous blood samples and needle biopsy
Study: NCT01439516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
Study: NCT01903460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00510835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Goal Directed Therapy (EGDT)
Description: Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized Standard Care (PSC)
Description: Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
Study: NCT06374368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: jejuno-ileal diversion
Description: The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The site of future anastomosis is identified (45 cm from ligament of Treitz on jejunum and 45 cm for the ileocoecal junction on ileum). The anastomosis between these two parts of jejunum and ileum is created by the means of linear stapler (45 mm).
Study: NCT02700477

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fenugreek seeds extract
Description: Fenugreek seed extract 500mg, BD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing Dicalcium Phosphate 500mg, BD
Study: NCT06374368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: jejuno-colic diversion
Description: The surgery is performed in general anesthesia with orotracheal intubation. The laparoscopic approach is used. After establishing pneumoperitoneum (insufluation of the abdominal cavity with CO2) the 1th. trocar and laparoscopic camera are introduced through small incision. After visual control of abdominal cavity additional 2-3 trocars for operating instruments are introduced. The anastomosis is created between jejunum (45 from ligament of Treitz) and transverse colon (behind the liver flexure).
Study: NCT03114319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: TNO155 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155 in combination with EGF816 (nazartinib)
Description: TNO155 for oral administration; EGF816 (nazartinib) for oral administration
Study: NCT03268772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD and IFO
Description: PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
Study: NCT02819921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate 100mg
Description: Pristiq 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine succinate 50mg
Description: Pristiq 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03050801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Altering the connectivity of trans-synaptic pathways
Study: NCT00102466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03572946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted prostate biopsy
Description: MRI-guided targeted prostate biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard biopsy
Description: Transperineal ultrasound guided prostate biopsy(SB).
Study: NCT03691909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences autologous adipose-derived mesenchymal stem cells
Study: NCT02234843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
Study: NCT03812393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
Study: NCT02918227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Search retrograde ejaculation
Description: Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
Study: NCT00178126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Protection Wheelchair Seat Cushion
Description: Cushion receiving CMS code for Skin Protection Wheelchair Cushion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Segmented Foam Wheelchair Seat Cushion
Description: General use class wheelchair seat cushion
Study: NCT02845362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sydney Swallow Questionnaire
Description: The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
Study: NCT02822144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT03718130

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
Description: The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study: NCT02234843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care
Study: NCT05356286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural electrical stimulation
Description: Electrical spinal cord stimulation will be used to modulate respiratory function during general anesthesia.
Study: NCT03164486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-αvβ6-BP
Description: Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
Study: NCT01576341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa (Sandoz)
Description: Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
Study: NCT03610256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SADI-S
Description: Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI \< 50
Study: NCT03718130

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
Description: The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)
Description: The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
Study: NCT03610256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB
Description: The laparoscopic Roux-en-Y Gastric Bypass will consist of:~* a small gastric pouch (about 30cc)~* an antecolic alimentary limb~* a gastro-jejunal anastomosis using a linear stapler~* a 150cm long alimentary limb~* a 50cm biliary limb~* a latero-lateral jejuno-jejunal anastomosis~* closure of the mesenteric defects
Study: NCT03649542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluidotherapy plus exercise
Description: The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
Study: NCT04227470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection
Description: Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 Injection
Description: Subcutaneous injection; Weekly administered for a period of 4 weeks. All subjects are treated with the testing drug, add on intravenous methylprednisolone (ivMP) with gradually reduce the dose then to oral prednisone. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Study: NCT03586765

Intervention type: OTHER
Intervention: Female urinary incontinence
Description: Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
Study: NCT01844765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
Study: NCT03810677

Intervention type: DEVICE
Intervention: ELVeS® Radial® 2ring slim fiber
Description: Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm